biotechnology

Apollomics, Inc. Company Operational Continuity Update

October 13, 2025 21:22 ET  | Source: Apollomics Inc. FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc.…

2 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinsons Disease

Event to be held October 14th at 4 p.m. EST October 09, 2025 07:00 ET  | Source: Gain Therapeutics, Inc.…

2 months ago

Pluri Subsidiary Coffeesai and Instituto del Caf de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico

October 08, 2025 09:00 ET  | Source: Pluri Inc. State-backed collaboration outlines a multi-phase, capital-light path from cell line development…

2 months ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led…

2 months ago

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

October 05, 2025 09:00 ET  | Source: Spyre Therapeutics, Inc. WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics,…

2 months ago

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional…

3 months ago

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program

The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program…

3 months ago

Vaxart Granted Extension by Nasdaq to Regain Compliance

August 29, 2025 08:00 ET  | Source: Vaxart, Inc. - Company must regain compliance with the Nasdaq Bid Price Rule…

4 months ago

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…

4 months ago

Caliber Enters 25th Year of Empowering Global Pharma with GxP Digital Solutions

HYDERABAD, India, Aug. 11, 2025 /PRNewswire/ -- Caliber, a leading global provider of GxP-compliant digital solutions for the life sciences…

4 months ago